Send to

Choose Destination
Res Rep Urol. 2017 Feb 23;9:27-35. doi: 10.2147/RRU.S125791. eCollection 2017.

Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients.

Author information

Sydney Adventist Hospital Clinical School, University of Sydney, Wahroonga, NSW.
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC; Australian Prostate Cancer Research Centre, Epworth Healthcare, Richmond, VIC.
Shire Urology, Miranda, NSW.
Australian Urology Associates, Malvern, VIC.
Department of Urology, Repatriation General Hospital, Daw Park, SA.
Ipsen Pty Ltd, Glen Waverley, VIC, Australia.



Prostate cancer is often comorbidly associated with lower urinary tract symptoms (LUTS), but few studies have assessed the effects of androgen deprivation therapy on LUTS in this patient group.


We conducted a prospective, noninterventional, multicenter, observational study to assess the effectiveness of triptorelin (11.25 mg every 12 weeks) over 48 weeks in men presenting with local stage T3/4 prostate cancer and moderate to severe LUTS (International Prostate Symptom Score [IPSS] >7) in a routine practice setting in Australia.


Of the 44 men who enrolled, effectiveness data were available for 39 men. By the end of the study, 30% of men no longer met the IPSS criteria for moderate to severe LUTS. The proportion of patients with moderate to severe LUTS was 69.6% (16/23) at week 48 and 76.9% (30/39) at the last available visit (coprimary outcomes). An IPSS reduction of ≥3 from week 0 was observed in 47% of men at week 4, 56% at week 24, 61% (14/23) at week 48, and 61.5% (24/39) at the last available visit. Quality of life was rated as mostly satisfied-to-delighted by 39.5% of patients at week 0, 53.9% at week 24, and 77.3% at week 48. Triptorelin was well tolerated with 8 treatment-related adverse events reported, half of which were hot flushes; 5 patients discontinued due to the reported treatment-related adverse events.


This observational study suggests that triptorelin improves moderate to severe LUTS in prostate cancer patients in a routine clinical practice setting.


GnRH agonist; IPSS

Conflict of interest statement

Disclosure DGM has received honoraria for speaking and consulting services from Ipsen Pty Ltd. JPG has received a research grant and honoraria for consulting services from Ipsen Pty Ltd. APS is an employee of Ipsen Pty Ltd. The authors report no other conflicts of interest in this work.

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center